Warning: The NCBI web site requires JavaScript to function. more...
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL.
Arthritis Res Ther. 2006;8(1):R3.
Related citations
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.
Joint Bone Spine. 2009 May;76(3):248-53. Epub 2009 Feb 8.
[Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.
Recenti Prog Med. 2006 Mar;97(3):134-9. Italian.
Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, Aravena O, Pesce B, Sabugo F, Aguillón JC.
Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1067-73.
Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
J Clin Immunol. 2008 Sep;28(5):445-55. Epub 2008 Jun 28.
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
Ann Rheum Dis. 2004 Oct;63(10):1218-21.
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.
Ann Rheum Dis. 2005 Feb;64(2):299-302. Epub 2004 May 27.
Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.
J Rheumatol. 2008 Oct;35(10):1972-7. Epub 2008 Sep 1.
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM.
Rheumatol Int. 2005 Nov;26(1):58-62. Epub 2005 Feb 23.
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C.
Ann Rheum Dis. 2007 Mar;66(3):302-7. Epub 2006 Nov 1.
Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up.
Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P.
Autoimmunity. 2008 Feb;41(1):87-91.
Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
Clin Rheumatol. 2008 Jan;27(1):91-5. Epub 2007 Oct 10.
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
Arthritis Res Ther. 2004;6(3):R264-72. Epub 2004 Apr 26.
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT.
Ann Rheum Dis. 2006 Jan;65(1):35-9. Epub 2005 Jun 23.
Autoimmunity and anti-TNF-alpha agents.
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P.
Ann N Y Acad Sci. 2005 Jun;1051:559-69. Review.
Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM.
South Med J. 2006 Nov;99(11):1209-15.
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
Arthritis Res Ther. 2004;6(6):R535-43. Epub 2004 Sep 23.
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
Arthritis Rheum. 2000 Nov;43(11):2383-90.
IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, Hamann D, Dijkmans BA, Lems WF.
J Rheumatol. 2008 Mar;35(3):425-8.
Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP.
Ann Rheum Dis. 2005 Aug;64(8):1224-6.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on